{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:23:28Z","timestamp":1763198608031,"version":"3.45.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01552-6","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:01:38Z","timestamp":1758880898000},"page":"3449-3461","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Outcomes of Topical 5% Imiquimod Treatment for Lentigo Maligna: A Systematic Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Pablo","family":"Balado-Sim\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Hern\u00e1ndez-Santacana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4704-6132","authenticated-orcid":false,"given":"Daniel","family":"Morgado-Carrasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"1552_CR1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2133.1987.tb05843.x","volume":"116","author":"MA Weinstock","year":"1987","unstructured":"Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol. 1987;116:303\u201310.","journal-title":"Br J Dermatol"},{"key":"1552_CR2","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.jid.2016.06.014","volume":"136","author":"K Greveling","year":"2016","unstructured":"Greveling K, Wakkee M, Nijsten T, van den Bos RR, Hollestein LM. Epidemiology of lentigo maligna and lentigo maligna melanoma in the Netherlands, 1989\u20132013. J Invest Dermatol. 2016;136:1955\u201360.","journal-title":"J Invest Dermatol"},{"key":"1552_CR3","first-page":"CD010308","volume":"2014","author":"T Tzellos","year":"2014","unstructured":"Tzellos T, Kyrgidis A, Mocellin S, Chan AW, Pilati P, Apalla Z. Interventions for melanoma in situ, including lentigo maligna. Cochrane Database Syst Rev. 2014;2014:CD010308.","journal-title":"Cochrane Database Syst Rev"},{"key":"1552_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000502470","volume":"236","author":"M Robinson","year":"2019","unstructured":"Robinson M, Primiero C, Guitera P, et al. Evidence-based clinical practice guidelines for the management of patients with lentigo maligna. Dermatology. 2019;236:111\u20136.","journal-title":"Dermatology"},{"key":"1552_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","volume":"22","author":"SM Swetter","year":"2024","unstructured":"Swetter SM, Tsao H, Bichakjian CK, et al. NCCN guidelines\u00ae insights: melanoma: cutaneous, version 2.2024: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2024;22:290\u20138.","journal-title":"J Natl Compr Canc Netw"},{"key":"1552_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae364","author":"MA Taylor","year":"2024","unstructured":"Taylor MA, Thomas SI, Sharma D, Voss VB, Wysong A. Improved disease-specific survival in lentigo maligna treated with Mohs surgery over wide local excision: a retrospective cohort analysis. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae364.","journal-title":"Br J Dermatol"},{"key":"1552_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/jdv.13252","volume":"30","author":"T Read","year":"2016","unstructured":"Read T, Noonan C, David M, et al. A systematic review of non-surgical treatments for lentigo maligna. J Eur Acad Dermatol Venereol. 2016;30:748\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1552_CR8","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s13555-023-00993-1","volume":"13","author":"S Vaienti","year":"2023","unstructured":"Vaienti S, Calzari P, Nazzaro G. Topical treatment of melanoma in situ, lentigo maligna, and lentigo maligna melanoma with imiquimod cream: a systematic review of the literature. Dermatol Ther. 2023;13:2187\u2013215.","journal-title":"Dermatol Ther"},{"key":"1552_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/jdv.14085","volume":"31","author":"D Tio","year":"2017","unstructured":"Tio D, van der Woude J, Prinsen CAC, Jansma EP, Hoekzema R, van Montfrans C. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures. J Eur Acad Dermatol Venereol. 2017;31:616\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1552_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2015.05.022","volume":"73","author":"AN Mora","year":"2015","unstructured":"Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. J Am Acad Dermatol. 2015;73:205\u201312.","journal-title":"J Am Acad Dermatol"},{"key":"1552_CR11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jaad.2016.02.1150","volume":"74","author":"KL Connolly","year":"2016","unstructured":"Connolly KL, Nijhawan RI, Dusza SW, Busam KJ, Nehal KS. Time to local recurrence of lentigo maligna: implications for future studies. J Am Acad Dermatol. 2016;74:1247\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1552_CR12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1097\/DSS.0000000000001118","volume":"43","author":"KL Connolly","year":"2017","unstructured":"Connolly KL, Hibler B, Lee E, Rossi A, Busam KJ, Nehal K. Locally recurrent lentigo maligna and lentigo maligna melanoma: characteristics and time to recurrence after surgery. Dermatol Surg. 2017;43:792\u20137.","journal-title":"Dermatol Surg"},{"key":"1552_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.36849\/JDD.5660","volume":"20","author":"M Chambers","year":"2021","unstructured":"Chambers M, Swetter SM, Baker C, Saunders E, Chapman MS. Topical imiquimod for lentigo maligna: survival analysis of 103 cases with 17\u00a0years follow-up. J Drugs Dermatol. 2021;20:346\u20138.","journal-title":"J Drugs Dermatol"},{"key":"1552_CR14","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.3390\/cancers15051546","volume":"15","author":"SM Seyed Jafari","year":"2023","unstructured":"Seyed Jafari SM, Folini-Huesser F, Cazzaniga S, Hunger RE. Long-term follow-up of lentigo maligna patients treated with imiquimod 5% cream. Cancers. 2023;15:1546.","journal-title":"Cancers"},{"key":"1552_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaad.2015.08.031","volume":"74","author":"M Gautschi","year":"2016","unstructured":"Gautschi M, Oberholzer PA, Baumgartner M, Gadaldi K, Yawalkar N, Hunger RE. Prognostic markers in lentigo maligna patients treated with imiquimod cream: a long-term follow-up study. J Am Acad Dermatol. 2016;74:81-87.e1.","journal-title":"J Am Acad Dermatol"},{"key":"1552_CR16","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/j.1365-2133.2009.09032.x","volume":"160","author":"AM Powell","year":"2009","unstructured":"Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol. 2009;160:994\u20138.","journal-title":"Br J Dermatol"},{"key":"1552_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/bjd.14311","volume":"174","author":"AC Kai","year":"2016","unstructured":"Kai AC, Richards T, Coleman A, Mallipeddi R, Barlow R, Craythorne EE. Five-year recurrence rate of lentigo maligna after treatment with imiquimod. Br J Dermatol. 2016;174:165\u20138.","journal-title":"Br J Dermatol"},{"key":"1552_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/ced.13896","volume":"44","author":"M Papanikolaou","year":"2019","unstructured":"Papanikolaou M, Lawrence CM. Long-term outcomes of imiquimod-treated lentigo maligna. Clin Exp Dermatol. 2019;44:631\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1552_CR19","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jaad.2015.02.008","volume":"72","author":"SM Swetter","year":"2015","unstructured":"Swetter SM, Chen FW, Kim DD, Egbert BM. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type. J Am Acad Dermatol. 2015;72:1047\u201353.","journal-title":"J Am Acad Dermatol"},{"key":"1552_CR20","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.3390\/cancers13194913","volume":"13","author":"AE Verz\u00ec","year":"2021","unstructured":"Verz\u00ec AE, Micali G, Lacarrubba F. Line-field confocal optical coherence tomography may enhance monitoring of superficial basal cell carcinoma treated with Imiquimod 5% cream: a pilot study. Cancers (Basel). 2021;13:4913.","journal-title":"Cancers (Basel)"},{"key":"1552_CR21","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/jdv.17135","volume":"35","author":"H Collgros","year":"2021","unstructured":"Collgros H, Rodriguez-Lomba E, Regio-Pereira A, Lo SN, Scolyer RA, Guitera P. Lentiginous melanoma (lentigo maligna and lentigo maligna melanoma) in Australia: clinicopathological characteristics, management and recurrence rates after 10-year follow-up at a tertiary centre. J Eur Acad Dermatol Venereol. 2021;35:1315\u201322.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1552_CR22","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/DSS.0000000000000466","volume":"41","author":"KH Gardner","year":"2015","unstructured":"Gardner KH, Hill DE, Wright AC, et al. Upstaging from melanoma in situ to invasive melanoma on the head and neck after complete surgical resection. Dermatol Surg. 2015;41:1122.","journal-title":"Dermatol Surg"},{"key":"1552_CR23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/j.1524-4725.2010.01618.x","volume":"36","author":"JRI Debloom","year":"2010","unstructured":"Debloom JRI, Zitelli JA, Brodland DG. The invasive growth potential of residual melanoma and melanoma in situ. Dermatol Surg. 2010;36:1251.","journal-title":"Dermatol Surg"},{"key":"1552_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/DSS.0000000000004014","volume":"50","author":"JM Soh","year":"2024","unstructured":"Soh JM, Brodland DG, Zitelli JA. Clinical characteristics of marginally recurrent melanoma after primary excision: a multisite retrospective analysis of 140 cases referred for Mohs surgery. Dermatol Surg. 2024;50:131.","journal-title":"Dermatol Surg"},{"key":"1552_CR25","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/bjd.15112","volume":"176","author":"JR Marsden","year":"2017","unstructured":"Marsden JR, Fox R, Boota NM, et al. Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT-1 study. Br J Dermatol. 2017;176:1148\u201354.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01552-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01552-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01552-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T09:22:13Z","timestamp":1763198533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01552-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01552-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Pablo Balado-Sim\u00f3 and Marc Hern\u00e1ndez-Santacana have nothing to disclose. Daniel Morgado-Carrasco is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Daniel Morgado-Carrasco was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}